PMID- 20942233
OWN - NLM
STAT- MEDLINE
DCOM- 20110825
LR  - 20171116
IS  - 2096-7993 (Print)
IS  - 2096-7993 (Linking)
VI  - 24
IP  - 15
DP  - 2010 Aug
TI  - [Study of mRNA expression level and hypermethylation of CHFR promoter in the 
      laryngeal squamous cell carcinoma tissue].
PG  - 673-7
AB  - OBJECTIVE: To explore the relationship between the level of expression and 
      hypermethylation of the CHFR gene and the occurrence and development of laryngeal 
      squamous cell carcinoma (LSCC). METHOD: The mRNA expression and promoter 
      hypermethylation were detected by Realtime fluro-genetic quantitative PCR and 
      methylation specific PCR in 50 LSCCs (LSCC group) and 15 normal laryngeal tissue 
      (control group). RESULT: 1) CHFR mRNA was shown in the control group, while the 
      mRNA was loss expression in the 2 LSCC (4%), and the level of mRNA expression was 
      significantly lower in the LSCC group. The relative ratio was 0.50 +/- 0.12, 
      which is 0.30 +/- 0.04 at the early stage of the LSCC and 0.70 +/- 0.21 at the 
      advanced stage, respectively. The discrepancy had statistical significance 
      (P<0.01). 2) The methylation rate of CHFR was 22% (11/50) in the LSCC tissues, 
      which was not found in the normal tissues. The aberrant methylation of CHFR was 
      observed in 10 of the patients at the stage I and stage II of LSCC , in 1 of the 
      patients at the stage III, and was absent at the stage IV. There was significant 
      difference between the aberrant methylation of CHFR and the stage of carcinoma 
      (P<0.01). 3) The mRNA expression level of the aberrant methylation patients was 
      0.11 +/- 0.05, which was significantly lower than that of the unmethylation 
      patients 0.75 +/- 0.13. Gene inactivation was observed in 2 of the 11 patients 
      with the aberrant promoter methylation. The methylation was associated with the 
      expression of mRNA, with the correlation coefficient 0.387 (P<0.05). CONCLUSION: 
      Hypermethylation of CHFR gene promoter is associated with loss or lower 
      expression of CHFR mRNA in the LSCCs, and it may contribute to the occurrence and 
      development of LSCC. The promoter aberrant methylation of CHFR may be one of the 
      early diagnostic and therapeutic marker genes.
FAU - He, Lixia
AU  - He L
AD  - Department of Otolaryngology, the Shengjing Hospital of China Medical University, 
      Shenyang, 110004, China.
FAU - Ji, Wenyue
AU  - Ji W
FAU - Yang, Jing
AU  - Yang J
FAU - Zhao, Xudong
AU  - Zhao X
LA  - chi
PT  - Journal Article
PL  - China
TA  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
JT  - Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical 
      otorhinolaryngology, head, and neck surgery
JID - 101303164
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Poly-ADP-Ribose Binding Proteins)
RN  - 0 (RNA, Messenger)
RN  - EC 2.3.2.27 (CHFR protein, human)
RN  - EC 2.3.2.27 (Ubiquitin-Protein Ligases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*genetics/pathology
MH  - Cell Cycle Proteins/*genetics
MH  - CpG Islands
MH  - *DNA Methylation
MH  - Female
MH  - Gene Silencing
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Proteins/*genetics
MH  - Neoplasm Staging
MH  - Poly-ADP-Ribose Binding Proteins
MH  - Promoter Regions, Genetic
MH  - RNA, Messenger/genetics
MH  - Ubiquitin-Protein Ligases
EDAT- 2010/10/15 06:00
MHDA- 2011/08/27 06:00
CRDT- 2010/10/15 06:00
PHST- 2010/10/15 06:00 [entrez]
PHST- 2010/10/15 06:00 [pubmed]
PHST- 2011/08/27 06:00 [medline]
PST - ppublish
SO  - Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2010 Aug;24(15):673-7.